Effects of haloperidol and its pyridinium metabolite on plasma membrane permeability and fluidity in the rat brain

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 31, Issue 4, 2007, Pages 848-857

  Murata, Tetsuhito ^a   Maruoka, Nobuyuki ^a   Omata, Naoto ^a   Takashima, Yasuhiro ^a   Igarashi, Kazuo ^b   Kasuya, Fumiyo ^c   Fujibayashi, Yasuhisa ^a   Wada, Yuji ^a  

^a UNIVERSITY OF FUKUI   (Japan)

^b VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

^c KOBE GAKUIN UNIVERSITY   (Japan)

Author keywords

Haloperidol pyridinium; Membrane fluidity; Membrane permeability; Neurotoxicity; Parkinsonism; Tardive dyskinesia

Indexed keywords

HALOPERIDOL; PYRIDINIUM DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANISOTROPY; ARTICLE; CELL DAMAGE; CELL MEMBRANE; CELL MEMBRANE FLUIDITY; CONTROLLED STUDY; CYTOPLASM; DRUG POTENCY; EVALUATION; FLUIDIZATION; MALE; MEMBRANE PERMEABILITY; MEMBRANE TRANSPORT; MOLECULAR PROBE; NONHUMAN; PATHOGENESIS; RAT; SPECTROFLUOROMETRY;

ANIMALS; ANISOTROPY; AUTORADIOGRAPHY; BRAIN; BRAIN MAPPING; CELL MEMBRANE; CELL MEMBRANE PERMEABILITY; FLUORODEOXYGLUCOSE F18; HALOPERIDOL; L-LACTATE DEHYDROGENASE; MALE; PYRIDINIUM COMPOUNDS; RADIOPHARMACEUTICALS; RATS; RATS, WISTAR; STATISTICS, NONPARAMETRIC; THIOBARBITURIC ACID REACTIVE SUBSTANCES; TIME FACTORS;

EID: 34247531875     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2007.01.023     Document Type: Article

References (86)

1. 3H-adenine, and lactate dehydrogenase. J Lab Clin Med 106 (1985) 253-261
2. Ashwell J.D., Schwartz R.H., Mitchell J.B., and Russo A. Effect of gamma radiation on resting B lymphocytes. I. Oxygen-dependent damage to the plasma membrane results in increased permeability and cell enlargement. J Immunol 136 (1986) 3649-3656
3. Avdulov N.A., Chochina S.V., Igbavboa U., O'Hare E.O., Schroeder F., Cleary J.P., et al. Amyloid β-peptides increase annular and bulk fluidity and induce lipid peroxidation in brain synaptic plasma membranes. J Neurochem 68 (1997) 2086-2091
4. Avent K.M., Riker R.R., Fraser G.L., Van der Schyf C.J., Usuki E., and Pond S.M. Metabolism of haloperidol to pyridinium species in patients receiving high doses intravenously: is HPTP an intermediate?. Life Sci 61 (1997) 2383-2390
5. Balijepalli S., Boyd M.R., and Ravindranath V. Inhibition of mitochondrial complex I by haloperidol: the role of thiol oxidation. Neuropharmacology 38 (1999) 567-577
6. Bloomquist J., King E., Wright A., Mytilineou C., Kimura K., Castagnoli K., et al. 1-Methyl-4-phenylpyridinium-like neurotoxicity of a pyridinium metabolite derived from haloperidol: cell culture and neurotransmitter uptake studies. J Pharmacol Exp Ther 270 (1994) 822-830
7. Bryan-Lluka L.J., Siebert G.A., and Pond S.M. Potencies of haloperidol metabolites as inhibitors of the human noradrenaline, dopamine and serotonin transporters in transfected COS-7 cells. Naunyn Schmiedeberg's Arch Pharmacol 360 (1999) 109-115
8. Burkhardt C., Kelly J.P., Lim Y.H., Filley C.M., and Parker Jr. W.D. Neuroleptic medications inhibit complex I of the electron transport chain. Ann Neurol 33 (1993) 512-517
9. Eyles D.W., McLennan H.R., Jones A., McGrath J.J., Stedman T.J., and Pond S.M. Quantitative analysis of two pyridinium metabolites of haloperidol in patients with schizophrenia. Clin Pharmacol Ther 56 (1994) 512-520
10. Eyles D.W., McGrath J.J., and Pond S.M. Formation of pyridinium species of haloperidol in human liver and brain. Psychopharmacology 125 (1996) 214-219
11. Eyles D.W., Avent K.M., Stedman T.J., and Pond S.M. Two pyridinium metabolites of haloperidol are present in the brain of patients at post-mortem. Life Sci 60 (1997) 529-534
12. Fang J., and Yu P.H. Effect of haloperidol and its metabolites on dopamine and noradrenaline uptake in rat brain slices. Psychopharmacology (Berl) 121 (1995) 379-384
13. +) towards cultured dopaminergic neuroblastoma cells. Psychopharmacology (Berl) 121 (1995) 373-378
14. Fang J., Baker G.B., Silverstone P.H., and Coutts R.T. Involvement of CYP3A4 and CYP2D6 in the metabolism of haloperidol. Cell Mol Neurobiol 17 (1997) 227-233
15. Fang J., McKay G., Song J., Remillrd A., Li X., and Midha K. In vitro characterization of the metabolism of haloperidol using recombinant cytochrome p450 enzymes and human liver microsomes. Drug Metab Dispos 29 (2001) 1638-1643
16. Forsman A., and Ohman R. Studies on serum protein binding of haloperidol. Curr Ther Res Clin Exp 21 (1977) 245-255
17. Galili-Mosberg R., Gil-Ad I., Weizman A., Weizman A., Melamed E., and Offen D. Haloperidol-induced neurotoxicity - possible implications for tardive dyskinesia. J Neural Transm 107 (2000) 479-490
18. Gerlach J., and Casey D.E. Tardive dyskinesia. Acta Psychiatr Scand 77 (1988) 369-378
19. Goldstein D.B. The effects of drugs on membrane fluidity. Annu Rev Pharmacol Toxicol 24 (1984) 43-64
20. Gray E.G., and Whittaker V.P. The isolation of nerve endings from brain: an electron-microscopic study of cell fragments derived by homogenization and centrifugation. J Anat 96 (1962) 79-88
21. Grohmann R., Koch R., and Schmidt L.G. Extrapyramidal symptoms in neuroleptic recipients. Agents Actions Suppl 29 (1990) 71-82
22. 18F]-fluoro-2-deoxy-d-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 27 (1986) 235-238
23. +-ATPase activity in mouse synaptosomes. Neurotoxicol Teratol 15 (1993) 345-352
24. Igarashi K., and Castagnoli Jr. N. Determination of the pyridinium metabolite derived from haloperidol in brain tissue, plasma and urine by high-performance liquid chromatography with fluorescence detection. J Chromatogr 579 (1992) 277-283
25. + found in rat brain following ip administration of HP. Life Sci 57 (1995) 2439-2446
26. Igarashi K., Matsubara K., Kasuya F., Fukui M., Idzu T., and Castagnoli Jr. N. Effect of a pyridinium metabolite derived from haloperidol on the activities of striatal tyrosine hydroxylase in freely moving rats. Neurosci Lett 214 (1996) 183-186
27. Iwahashi K., Anemo K., Nakamura K., Fukunishi I., and Igarashi K. Analysis of the metabolism of haloperidol and its neurotoxic pyridinium metabolite in patients with drug-induced parkinsonism. Neuropsychobiology 44 (2001) 126-128
28. Janero D.R. Malondialdehyde and thiobarbituric acid-reactivity as diagnostic indices of lipid peroxidation and peroxidative tissue injury. Free Radic Biol Med 9 (1990) 515-540
29. Jeste D.V., and Caligiuri M.P. Tardive dyskinesia. Schizophr Bull 19 (1993) 303-315
30. +) within catecholaminergic neurons. Neurotoxicology 12 (1991) 285-302
31. Kalgutkar A.S., Zhou S., Fahmi O.A., and Taylor T.J. Influence of lipophilicity on the interactions of N-alkyl-4-phenyl-1,2,3,6-tetrahydropyridines and their positively charged N-alkyl-4-phenylpyridinium metabolites with cytochrome P450 2D6. Drug Metab Dispos 31 (2003) 596-605
32. Katsu T., Kobayashi H., Hirota T., Fujita Y., Sato K., and Nagai U. Structure-activity relationship of gramicidin S analogues on membrane permeability. Biochim Biophys Acta 899 (1987) 159-170
33. Katsu T., Kuroko M., Morikawa T., Sanchika K., Fujita Y., Yamamura H., et al. Mechanism of membrane damage induced by the amphipathic peptides gramicidin S and melittin. Biochim Biophys Acta 983 (1989) 135-141
34. Katsu T., Nakao S., and Iwanaga S. Mode of action of an antimicrobial peptide, tachyplesin I, on biomembranes. Biol Pharm Bull 16 (1993) 178-181
35. Kim K.C., and Burkman A.M. Haloperidol causes irreversible damage to rat anterior pituitary lactotropes in culture. Res Commun Chem Pathol Pharmacol 36 (1982) 179-185
36. Klawans H.L., Goetz C.G., and Perlik S. Tardive dyskinesia: review and update. Am J Psychiatry 137 (1980) 900-908
37. Koh J.Y., and Choi D.W. Quantitative determination of glutamate mediated cortical neuronal injury in cell culture by lactate dehydrogenase efflux assay. J Neurosci Methods 20 (1987) 83-90
38. Kristensen S.R., and Horder M. Release of enzymes from quiescent fibroblasts during ATP depletion. Enzyme 39 (1988) 205-212
39. Kudo S., and Ishizaki T. Pharmacokinetics of haloperidol: an update. Clin Pharmacokinet 37 (1999) 435-456
40. Langston J.W., Ballard P., Tetrud J.W., and Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219 (1983) 979-980
41. Malik J.K., Schwarz L.R., and Wiebel F.J. Assessment of membrane damage in continuous cultures of mammalian cells. Chem Biol Interact 45 (1983) 29-42
42. Manor D., and Sadeh M. Muscle fibre necrosis induced by intramuscular injection of drugs. Br J Exp Pathol 70 (1989) 457-462
43. Markey S.P., and Schmuff N.R. The pharmacology of the parkinsonian syndrome producing neurotoxin MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) and structurally related compounds. Med Res Rev 6 (1986) 389-429
44. Marsden C.D., and Jenner P. The pathophysiology of extrapyramidal side-effects of neuroleptic drugs. Psychol Med 10 (1980) 55-72
45. Mitchell I.J., Cooper A.C., Griffiths M.R., and Cooper A.J. Acute administration of haloperidol induces apoptosis of neurones in the striatum and substantia nigra in the rat. Neuroscience 109 (2002) 89-99
46. Murata T., Omata N., Fujibayashi Y., Waki A., Sadato N., Yoshida S., et al. Dynamic changes in glucose metabolism of living rat brain slices induced by hypoxia and neurotoxic chemical-loading revealed by positron autoradiography. J Neural Transm 106 (1999) 1075-1087
47. Noji S., Takahashi T., and Kon H. A spin-label study of the correlation between stomatocyte formation and membrane fluidization of erythrocytes. Biochem Pharmacol 31 (1982) 3173-3180
48. Ohyashiki T., Sakata N., and Matsui K. A decrease of lipid fluidity of the porcine intestinal brush-border membranes by treatment with malondialdehyde. J Biochem (Tokyo) 111 (1992) 419-423
49. Omata N., Murata T., Fujibayashi Y., Waki A., Sadato N., Yoshimoto M., et al. Hypoxic but not ischemic neurotoxicity of free radicals revealed by dynamic changes in glucose metabolism of fresh rat brain slices on positron autoradiography. J Cereb Blood Flow Metab 20 (2000) 350-358
50. Pai B.N., Janakiramaiah N., Gangadhar B.N., and Ravindranath V. Depletion of glutathione and enhanced lipid peroxidation in the CSF of acute psychotics following haloperidol administration. Biol Psychiatry 36 (1994) 489-491
51. Pappu A.S., and Hauser G. Alterations of phospholipid metabolism in rat cerebral cortex mince induced by cationic amphiphilic drugs. J Neurochem 37 (1981) 1006-1014
52. Paxinos G., and Watson C. The rat brain in stereotaxic coordinates. 4th edn. (1998), Academic Press, San Diego
53. Post A., Holsboer F., and Behl C. Induction of NF-κB activity during haloperidol-induced oxidative toxicity in clonal hippocampal cells: suppression of NF-κB and neuroprotection by antioxidants. J Neurosci 18 (1998) 8236-8246
54. Rajput A.H., Rozdilsky B., Hornykiewicz O., Shannak K., Lee T., and Seeman P. Reversible drug-induced parkinsonism. Clinicopathologic study of two cases. Arch Neurol 39 (1982) 644-646
55. Rissanen E., Krumschnabel G., and Nikinmaa M. Dehydroabietic acid, a major component of wood industry effluents, interferes with cellular energetics in rainbow trout hepatocytes. Aquat Toxicol 62 (2003) 45-53
56. +-like neurotoxicity of a pyridinium metabolite derived from haloperidol: in vivo microdialysis and in vitro mitochondrial studies. J Pharmacol Exp Ther 268 (1994) 380-387
57. Sagara Y. Induction of reactive oxygen species in neurons by haloperidol. J Neurochem 71 (1998) 1002-1012
58. Saporito M.S., Heikkila R.E., Youngster S.K., Nicklas W.J., and Geller H.M. Dopaminergic neurotoxicity of 1-methyl-4-phenylpyridinium analogs in cultured neurons: relationship to the dopamine uptake system and inhibition of mitochondrial respiration. J Pharmacol Exp Ther 260 (1992) 1400-1409
59. + in both electron transport particles and intact mitochondria. Biochem Biophys Res Commun 161 (1989) 809-818
60. Seeman P., Staiman A., Lee T., and Chau-Wong M. The membrane actions of tranquilizers in relation to neuroleptic-induced parkinsonism and tardive dyskinesia. Adv Biochem Psychopharmacol 9 (1974) 137-148
61. Sergent O., Pereira M., Belhomme C., Chevanne M., Huc L., and Lagadic-Gossmann D. Role for membrane fluidity in ethanol-induced oxidative stress of primary rat hepatocytes. J Pharmacol Exp Ther 313 (2005) 104-111
62. Shinitzky M., and Inbar M. Microviscosity parameters and protein mobility in biological membranes. Biochim Biophys Acta 433 (1976) 133-149
63. Shinitzky M., and Barenholz Y. Fluidity parameters of lipid regions determined by fluorescence polarization. Biochim Biophys Acta 515 (1978) 367-394
64. Shivakumar B.R., and Ravindranath V. Oxidative stress induced by administration of the neuroleptic drug haloperidol is attenuated by higher doses of haloperidol. Brain Res 595 (1992) 256-262
65. Shivakumar B.R., and Ravindranath V. Oxidative stress and thiol modification induced by chronic administration of haloperidol. J Pharmacol Exp Ther 265 (1993) 1137-1141
66. Siebert G.A., Pond S.M., and Bryan-Lluka L.J. Further characterisation of the interaction of haloperidol metabolites with neurotransmitter transporters in rat neuronal cultures and in transfected COS-7 cells. Naunyn Schmiedeberg's Arch Pharmacol 361 (2000) 255-264
67. Silvestri S., Seeman M.V., Negrete J.C., Houle S., Shammi C.M., Remington G.J., et al. Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study. Psychopharmacology (Berl) 152 (2000) 174-180
68. Subramanyam B., Rollema H., Woolf T., and Castagnoli Jr. N. Identification of a potentially neurotoxic pyridinium metabolite of haloperidol in rats. Biochem Biophys Res Commun 166 (1990) 238-244
69. Subramanyam B., Pond S.M., Eyles D.W., Whiteford H.A., Fouda H.G., and Castagnoli Jr. N. Identification of potentially neurotoxic pyridinium metabolite in the urine of schizophrenic patients treated with haloperidol. Biochem Biophys Res Commun 181 (1991) 573-578
70. Subramanyam B., Woolf T., and Castagnoli Jr. N. Studies on the in vitro conversion of haloperidol to a potentially neurotoxic pyridinium metabolite. Chem Res Toxicol 4 (1991) 123-128
71. +-ATPase activity and membrane fluidity in mouse synaptosomes. Neurotoxicol Teratol 16 (1994) 575-582
72. Tanii H., Zhang X.P., and Ohyashiki T. In vitro influences of alcohols on mouse synaptosomes, and structure-activity relationships. Arch Toxicol 69 (1995) 617-623
73. Tipton K.F., and Singer T.P. Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. J Neurochem 61 (1993) 1191-1206
74. Ulrich S., Wurthmann C., Brosz M., and Meyer F.P. The relationship between serum concentration and therapeutic effect of haloperidol in patients with acute schizophrenia. Clin Pharmacokinet 34 (1998) 227-263
75. Ulrich S., Neuhof S., Braun V., Danos P., Pester U., and Hoy L. Disposition of haloperidol pyridinium and reduced haloperidol pyridinium in schizophrenic patients: no relationship with clinical variables during short-term treatment. J Clin Psychopharmacol 20 (2000) 210-219
76. Ulrich S., Sandmann U., and Genz A. Serum concentrations of haloperidol pyridinium metabolites and the relationship with tardive dyskinesia and parkinsonism: a cross-section study in psychiatric patients. Pharmacopsychiatry 38 (2005) 171-177
77. Urano S., Asai Y., Makabe S., Matsuo M., Izumiyama N., Ohtsubo K., et al. Oxidative injury of synapse and alteration of antioxidative defense systems in rats, and its prevention by vitamin E. Eur J Biochem 245 (1997) 64-70
78. Usuki E., Pearce R., Parkinson A., and Castagnoli Jr. N. Studies on the conversion of haloperidol and its tetrahydropyridine dehydration product to potentially neurotoxic pyridinium metabolites by human liver microsomes. Chem Res Toxicol 9 (1996) 800-806
79. Usuki E., Bloomquist J.R., Freeborn E., Casagnoli K., Van Der Schyf C.J., and Castagnoli Jr. N. Metabolic studies on haloperidol and its tetrahydropyridinyl dehydration product (HPTP) in C57BL/6 mouse brain preparations. Neurotox Res 4 (2002) 51-58
80. Volles M.J., and Lansbury Jr. P.T. Vesicle permeabilization by protofibrillar α-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism. Biochemistry 41 (2002) 4595-4602
81. Volles M.J., Lee S.J., Rochet J.C., Shtilerman M.D., Ding T.T., Kessler J.C., et al. Vesicle permeabilization by protofibrillar α-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry 40 (2001) 7812-7819
82. Waddington J.L. Spontaneous orofacial movements induced in rodents by very long-term neuroleptic drug administration: phenomenology, pathophysiology and putative relationship to tardive dyskinesia. Psychopharmacology (Berl) 101 (1990) 431-447
83. Walum E., and Peterson A. Tritiated 2-deoxy-d-glucose as a probe for cell membrane permeability studies. Anal Biochem 120 (1982) 8-11
84. Wright A.M., Bempong J., Kirby M.L., Barlow R.L., and Bloomquist J.R. Effects of haloperidol metabolites on neurotransmitter uptake and release: possible role in neurotoxicity and tardive dyskinesia. Brain Res 788 (1998) 215-222
85. Wysowski D.K., and Baum C. Antipsychotic drug use in the United States, 1976-1985. Arch Gen Psychiatry 46 (1989) 929-932
86. Yokoyama H., Kasai N., Ueda Y., Niwa R., Konaka R., Mori N., et al. In vivo analysis of hydrogen peroxide and lipid radicals in the striatum of rats under long-term administration of a neuroleptic. Free Radic Biol Med 24 (1998) 1056-1060